|View printer-friendly version|
|Quidel to Hold Fourth Quarter and Full Year 2009 Results Conference Call on February 11, 2010|
SAN DIEGO, Jan 29, 2010 (BUSINESS WIRE) -- Quidel Corporation (NASDAQ:QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, will release fourth quarter and full year 2009 financial results after market close on Thursday, February 11, 2010.
Following the release of the results, Douglas C. Bryant, president and chief executive officer, and John M. Radak, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss those results and to answer questions.
To participate in the live call by telephone from the U.S., dial (800) 299-6183, or from outside the U.S. dial (617) 801-9713, and enter the passcode 92595346.
A live webcast of the call can be accessed at http://www.quidel.com, and the Web site replay will be available for 14 days. The telephone replay will be available for 48 hours beginning at 8:00 p.m. Eastern Time (5:00 p.m. Pacific Time) on February 11 by dialing (888) 286-8010 from the U.S., or (617) 801-6888 for international callers, and entering passcode 48031182.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point-of-care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue(R), Quidel's portfolio of products currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, respiratory syncytial virus, Fecal Occult Blood, Strep A, pregnancy, H. pylori and Chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel's Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with potential future point-of-care applications. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment have an impact on clinical outcomes and provide an economic benefit. For more information, visit http://www.quidel.com, http://www.colorectal-test.com, http://www.rsvtesting.com and http://www.flutest.com.
SOURCE: Quidel Corporation